TeedeHJ, HutchisonSK, ZoungasS. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab, 2007; 18:273–279.
5.
OsibogunOOO, KoladeO, HaysA, et al.A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health, 2022; 31:762–771.
6.
ChangAY, AyersC, MinhajuddinA, et al.Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol (Oxf), 2011; 74:89–96.
7.
TalbottEO, ZborowskiJ, RagerJ, StragandJR. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?. Vasc Health Risk Manag, 2008; 4:453–462.
8.
TalbottEO, ZborowskiJV, RagerJR, BoudreauxMY, EdmundowiczDA, GuzickDS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2004; 89:5454–5461.
9.
Calderon-MargalitR, SiscovickD, MerkinSS, et al.Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: The Coronary Artery Risk Development in Young Adults Women's study. Arterioscler Thromb Vasc Biol, 2014; 34:2688–2694.
10.
WildRA, CarminaE, Diamanti-KandarakisE, et al.Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab, 2010; 95:2038–2049.
11.
ArnettDK, BlumenthalRS, AlbertMA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation, 2019; 140:e563–e595.